When combined with Bevacizumab, UniPR1331 shows enhanced therapeutic efficacy, highlighting the value of Eph-targeted strategies in glioblastoma treatment (Festuccia et al., 2018). The gene discussed is EPHA1; the disease is glioblastoma.